Aptevo Therapeutics Inc. - 8-K Filing

Aptevo Therapeutics reports 21% of frontline AML patients treated with mipletamig triplet advanced to stem cell transplant (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR · October 26, 2026, 12:14 UTC

Tickers: $APVO

Read the full article at SEC EDGAR

Part of the story Aptevo Therapeutics Inc. - 8-K Filing (3 articles)

More Regulatory news

Boost Run Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
INTERFACE INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Virtuix Holdings Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:20 UTC
Neonode Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:18 UTC
Beyond Air, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:17 UTC
Carter Bankshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:12 UTC
Marvell Technology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
VISHAY INTERTECHNOLOGY INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
LATTICE SEMICONDUCTOR CORP - 4 Filing SEC EDGAR · November 12, 2026, 14:10 UTC